Wehler, Elizabeth
Lautsch, Dominik
Kowal, Stacey
Davies, Glenn
Briggs, Andrew
Li, Qianyi
Rajpathak, Swapnil
Alsumali, Adnan
Funding for this research was provided by:
Merck Sharp and Dohme
Article History
Accepted: 19 September 2020
First Online: 5 November 2020
Declarations
:
: This study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. This study is available via Springer Open Choice, with the fee paid for by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA.
: Adnan Alsumali, Dominik Lautsch, and Swapnil Rajpathak are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Glenn Davies was an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, at the time of the study. Andrew Briggs is a director and shareholder of Avalon Health Economics and received compensation from Merck & Co., Inc. as a consultant for this work. He has also been contracted by Bayer, Eisai, Janssen, Novartis, Sword Health, Amgen, and Daichii Sankyo and received compensation outside of the submitted work. Elizabeth Wehler is an employee of IQVIA, a consulting company that received funding from Merck & Co., Inc. to conduct the study as well as from other companies. Qianyi Li and Stacey Kowal were employees of IQVIA at the time of the study.
: Not applicable.
: Not applicable.
: Not applicable.
: The datasets generated during and/or analyzed during the current study are not publicly available as they contain proprietary data but are available from the corresponding author on reasonable request.
: Not applicable.
: All authors were involved in developing the model concept and analytic plan. Elizabeth Wehler, Qianyi Li and Stacey Kowal ran the analyses in the CDM and built the budget impact model in Excel. All authors discussed the results and contributed to the final manuscript writing and revisions.